Pages that link to "Q41050375"
Jump to navigation
Jump to search
The following pages link to Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen (Q41050375):
Displaying 24 items.
- Multiple viral ligands naturally presented by different class I molecules in transporter antigen processing-deficient vaccinia virus-infected cells (Q24294775) (← links)
- Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2 (Q24792515) (← links)
- Synthetic self-adjuvanting glycopeptide cancer vaccines (Q26777837) (← links)
- Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients (Q28361963) (← links)
- Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival (Q33584997) (← links)
- Bridging innate and adaptive antitumor immunity targeting glycans. (Q33960021) (← links)
- A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor (Q34390075) (← links)
- Diversity of natural self-derived ligands presented by different HLA class I molecules in transporter antigen processing-deficient cells (Q34650773) (← links)
- Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. (Q35012871) (← links)
- Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells (Q36131252) (← links)
- An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells (Q36648430) (← links)
- Improved Transgenic Mouse Model for Studying HLA Class I Antigen Presentation. (Q37260631) (← links)
- MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge (Q38091088) (← links)
- MUC1 (CD227): a multi-tasked molecule (Q38570769) (← links)
- MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model (Q40197046) (← links)
- Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1-8 peptide (Q40215247) (← links)
- O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma. (Q40338018) (← links)
- Immunization with a vaccine that combines the expression of MUC1 and B7 co-stimulatory molecules prolongs the survival of mice and delays the appearance of mouse mammary tumors (Q40620016) (← links)
- Comparative Immunogenicity of a Cytotoxic T Cell Epitope Delivered by Penetratin and TAT Cell Penetrating Peptides. (Q40654151) (← links)
- Expression of B7.1 in a MUC1-expressing mouse mammary epithelial tumour cell line inhibits tumorigenicity but does not induce autoimmunity in MUC1 transgenic mice (Q40934020) (← links)
- Targeted antigen delivery by an anti-class II MHC VHH elicits focused αMUC1(Tn) immunity. (Q41828763) (← links)
- Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide (Q47626278) (← links)
- Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. (Q54593166) (← links)
- Altered peptide ligands of myelin basic protein ( MBP87-99 ) conjugated to reduced mannan modulate immune responses in mice (Q57594229) (← links)